Vyome Biosciences

Vyome Biosciences is an innovation driven company, with a vision to develop novel treatments for resistant pathogens

Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development. Vyome Biosciences’ management team members are the leaders in the field, with deep expertise, demonstrated capability and a proven track record of successfully launching over 50 products in dermatology & other life sciences areas, and building visionary companies. Vyome’s development platform is completely risk mitigated. Vyome has a deep pipeline of IP based products targeting multiple indications. The *lead molecule (VB 1953)*, which targets the huge unmet need in the drug resistant acne prescription market, will be entering the clinical phase with *USFDA IND Application Filing in Q4 2015*. Vyome has state-of-the-art infrastructure facilities to carry out all its research and lab development work, with full-fledged formulation, analytical, chemistry, biology & molecular biology, clinical and the regulatory divisions. The infrastructure and the team enables Vyome to conceive ideas, develop them and commercialize them at a rapid pace.